CareDx Appoints John W. Hanna as its New President and Chief Executive Officer
16 Abril 2024 - 5:02PM
Business Wire
CareDx, Inc. (Nasdaq: CDNA) – The Transplant Company™ – a
leading precision medicine company focused on the discovery,
development, and commercialization of clinically differentiated,
high-value diagnostic solutions for transplant patients – has
appointed John W. Hanna as its new President and Chief Executive
Officer, and member of the Company’s Board of Directors, effective
April 15, 2024.
“John is an outstanding leader with a proven track record of
building high-performing teams that deliver consistent results.
With extensive experience in the molecular diagnostics and life
sciences tools industries, John is the right executive to bring
strategic leadership to CareDx to propel the company forward and
capitalize on future growth opportunities,” said Michael Goldberg,
CareDx Board Chairperson. “The Board and I have full confidence in
John’s ability, rooted in his passion for advancing innovative
technologies that improve patient outcomes, to build on our strong
foundation.”
"I am thrilled to join this exceptional team and Board of
Directors of CareDx in improving the lives of transplant patients
worldwide. CareDx provides hope to patients and their families that
they can live fulfilling lives knowing that we support them at
every step of their journey,” said John Hanna, CareDx President and
CEO. “I look forward to working closely with the talented
individuals at CareDx and the transplant clinical community to
harness our culture of scientific rigor and evidence generation in
driving further adoption of our existing and pipeline products. My
goal is to achieve sustainable and profitable growth from our
existing portfolio while also charting a path for future growth
through new innovations."
Hanna brings to CareDx over two decades of executive leadership
at the intersection of new technology development and revenue
growth in the molecular diagnostics and life sciences tools
industries. Hanna previously served as Chief Executive Officer of
Apton Biosystems, Inc., where he led the development of a high
throughput next-generation sequencing (NGS) platform for liquid
biopsy and other clinical applications. The company was acquired by
Pacific Biosciences of California, Inc. in August 2023, where he
served as Vice President of Corporate Development. Hanna previously
spent ten years at Veracyte, Inc., an oncology diagnostics company
in the fields of thyroid, lung, breast, and prostate cancer, where
he held numerous roles including Chief Commercial Officer and Vice
President of Marketing. Prior to Veracyte, Hanna held leadership
roles at Humana and IBM.
About CareDx – The Transplant Company
CareDx, Inc., headquartered in Brisbane, California, is a
leading precision medicine solutions company focused on the
discovery, development, and commercialization of clinically
differentiated, high-value healthcare solutions for transplant
patients and caregivers. CareDx offers testing services, products,
and digital healthcare solutions along the pre- and post-transplant
patient journey and is the leading provider of genomics-based
information for transplant patients. For more information, please
visit: www.CareDx.com.
Forward Looking Statements
This press release includes forward-looking statements related
to CareDx, Inc., including statements regarding the CEO. These
forward-looking statements are based upon information that is
currently available to CareDx and its current expectations, speak
only as of the date hereof, and are subject to risks and
uncertainties that could cause actual results to differ materially
from those projected, including risks related to general economic
and market factors and the other risks discussed in CareDx’s
filings with the SEC, including the Annual Report on Form 10-K for
the fiscal year ended December 31, 2023 filed by CareDx with the
SEC on February 28, 2024 and other reports that CareDx has filed
with the SEC. Any of these may cause CareDx’s actual results,
performance, or achievements to differ materially and adversely
from those anticipated or implied by CareDx’s forward-looking
statements. CareDx expressly disclaims any obligation, except as
required by law, or undertaking to update or revise any such
forward-looking statements.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20240416572209/en/
CareDx, Inc. Media Relations Anna Czene 818-731-2203
aczene@caredx.com
Investor Relations Greg Chodaczek investor@caredx.com
CareDx (NASDAQ:CDNA)
Gráfico Histórico do Ativo
De Abr 2024 até Mai 2024
CareDx (NASDAQ:CDNA)
Gráfico Histórico do Ativo
De Mai 2023 até Mai 2024